The global age-related macular degeneration (AMD) market was valued at $5.3 billion in 2015 and is expected to advance at a CAGR of 7.6% during the forecast period. AMD is a retinal disorder that is indicated by a change in the fundus. It is one of the most common forms of visual impairment prevalent in geriatric population across the globe. AMD is mainly the deterioration or degeneration of the macula, which eventually leads to the loss of vision.
Growing prevalence of chronic retinal disorders and expanding pipeline of AMD drugs are the key factors driving the growth of the age-related macular degeneration market, globally. Besides, increasing healthcare expenditure in developed and developing countries is supporting the market demand for AMD drugs. However, factors such as stringent regulatory environment and increasing off-label use of drugs are hindering the market growth to some extent.
Between the two types of AMD—wet and dry—wet AMD is expected to be the faster-growing category in the global age-related macular degeneration market during the forecast period. Growth in geriatric population and rise in prevalence of the disease are expected to drive the market in this category.
Globally, North America led the age-related macular degeneration market during the historical period and Asia-Pacific (APAC) is projected to the fastest-growing regional market for AMD drugs in the near future.
Some of the players having notable presence in the age-related macular degeneration market are Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Regeneron Pharmaceutical Inc., Ophthotech Corporation, Neurotech Pharmaceuticals Inc., GlaxoSmithKline plc, StemCells Inc., and Alimera Sciences Inc.
GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION
Market Segmentation by Type
Market Segmentation by Drug
Market Segmentation by Geography